Biotech company Regeneron (NASDAQ: REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.

Is now the time to buy REGN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Regeneron’s second quarter was marked by strong commercial execution and robust product demand, resulting in financial results that surpassed Wall Street’s expectations and a significant positive market reaction. Management attributed this performance to continued momentum for key products, such as Dupixent, EYLEA HD, and Libtayo, each reaching new sales highs. CEO Leonard Schleifer highlighted that Dupixent’s broad adoption across multiple indications and EYLEA HD’s growing physician uptake, especially after recent label expansions, were central to the company’s revenue growth. Schleifer also pointed to Libtayo’s expanded use in oncology as another meaningful contributor this quarter.

Looking forward, Regeneron’s guidance centers on continued growth from its core franchises and the advancement of its diverse pipeline across immunology, oncology, and rare diseases. Management emphasized upcoming regulatory milestones, including potential FDA approvals for cemdisiran in myasthenia gravis and garetosmab in fibrodysplasia ossificans progressiva. CFO Chris Fenimore noted that the repayment of the Sanofi development balance will allow Regeneron to fully realize its share of collaboration profits, supporting further pipeline investment. Schleifer added, “We expect upcoming data and product launches to be important catalysts for our long-term growth trajectory.”

Key Insights from Management’s Remarks

Management credited the quarter’s performance to new and existing product momentum, effective commercial execution, and an expanding pipeline, with notable positive developments in key franchises and R&D progress.

• Dupixent expansion: Growth was driven primarily by ongoing demand in established indications, new launches in areas such as chronic spontaneous urticaria and allergic fungal rhinosinusitis, and international market penetration. Management sees a long growth runway with additional age groups and geographies targeted.

• EYLEA HD adoption: EYLEA HD surpassed original EYLEA in U.S. net sales, fueled by recent FDA label expansions allowing broader dosing flexibility and new indications, as well as strong physician demand. The company is preparing for the launch of an EYLEA HD prefilled syringe, which management anticipates will further accelerate adoption.

• Libtayo growth: Libtayo’s sales momentum was attributed to increased adoption in non-melanoma skin cancers and non-small cell lung cancer. Management highlighted Libtayo’s capture of 20% of new-to-brand prescriptions in the U.S. lung cancer market, reflecting successful commercial efforts and clinical differentiation.

• Pipeline diversification: Regeneron advanced approximately 50 clinical programs, including significant progress in complement-mediated diseases, oncology, and obesity. Notable pipeline highlights included regulatory submissions for cemdisiran, progress in Factor XI anticoagulation, and advancing next-generation immunology assets to build on Dupixent’s success.

• Business development discipline: Management reiterated a measured approach to external opportunities, emphasizing value-creating M&A and continued prioritization of internal R&D investment. CFO Chris Fenimore explained that the end of the Sanofi repayment period will bolster collaboration revenue and support further capital deployment.

Drivers of Future Performance

Regeneron’s outlook is shaped by ongoing product launches, pipeline milestones, and the full realization of collaboration profits, with management highlighting both growth opportunities and competitive risks.

• New product approvals anticipated: Management expects potential FDA approvals for cemdisiran in generalized myasthenia gravis and garetosmab in fibrodysplasia ossificans progressiva within the year, both viewed as important drivers for future revenue streams and portfolio diversification.

• Ongoing investment in pipeline: The company plans to initiate late-stage studies for several pipeline assets, including Phase III trials for its obesity candidate and continued development of next-generation immunology and oncology treatments. Management believes these investments will position Regeneron for sustained growth but noted that R&D expenses will remain elevated as programs advance.

• Market and competitive risks: Management acknowledged increased competition in retinal disease due to EYLEA biosimilars and evolving treatment landscapes in immunology and oncology. They see continued innovation and product differentiation as essential to maintaining share and supporting margin stability amid these pressures.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) regulatory decisions for cemdisiran and garetosmab, which could expand Regeneron’s rare disease portfolio; (2) the commercial uptake and prescriber adoption of EYLEA HD, especially following the anticipated prefilled syringe launch; and (3) progress on key pipeline programs in obesity, oncology, and complement-mediated diseases. Additional attention will be paid to competitive dynamics in retinal and immunology markets as biosimilars and new entrants emerge.

Regeneron currently trades at $734.07, up from $695.42 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.